Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Wednesday, March 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. is set to announce its fourth quarter and fiscal year 2023 results on March 27, 2024. The company specializes in advanced gene editing using its proprietary ARCUS platform. This announcement indicates ongoing progress in their gene editing therapies, which include various sophisticated gene edits.
Price reaction · baseline $12.23 (2024-03-20 close) · hit after-hours · clean, no other DTIL news in the window
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The company is preparing to report significant financial results.
  • The ARCUS platform shows promise for sophisticated gene edits.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Mar. 20, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

When will Precision BioSciences report its results?

Precision BioSciences will report its fourth quarter and fiscal year 2023 results on March 27, 2024.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What type of therapies does Precision BioSciences develop?

The company develops in vivo gene editing therapies for sophisticated gene edits.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform fiscal year 2023
Last updated: Mar 20, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →